MUSCARINIC AGONISTS TO TREAT IMPULSE CONTROL DISORDERS
    1.
    发明申请
    MUSCARINIC AGONISTS TO TREAT IMPULSE CONTROL DISORDERS 审中-公开
    治疗肿瘤控制障碍的药物治疗

    公开(公告)号:US20100120752A1

    公开(公告)日:2010-05-13

    申请号:US12690822

    申请日:2010-01-20

    CPC分类号: A61K31/5513

    摘要: The invention relates to a novel use of compounds and pharmaceutically acceptable salts thereof, which are muscarinic, for example muscarine-1 (M1) agonists. These compounds are useful for the preparation of medicaments for treatment, amelioration or prevention of impulse control disorders. These include impulse control disorders ‘Not Elsewhere Classified,’ such as intermittent explosive disorder, pyromania, kleptomania, pathological gambling and trichotillomania, and impulse control disorders ‘Not Otherwise Specified,’ such as compulsive buying disorder, binge eating and binge drinking disorder, impulsive self-injurious behavior, sexual addictions, compulsive Internet use, and excessive mobile phone use.

    摘要翻译: 本发明涉及毒蕈碱的化合物及其药学上可接受的盐的新用途,例如毒蕈碱-1(M1)激动剂。 这些化合物可用于制备用于治疗,改善或预防冲动控制障碍的药物。 这些包括脉冲控制障碍“非其他分类”,如间歇性爆发性疾病,原发性幽门螺杆菌,轻度恐怖症,病理性赌博和拔毛病,以及冲动控制障碍“无其他指定”,如强迫性购买障碍,暴饮暴食和暴饮暴食,冲动 自我伤害行为,性成瘾,互联网强制使用和手机使用过多。

    MUSCARINIC AGONISTS TO TREAT IMPULSE CONTROL DISORDERS
    2.
    发明申请
    MUSCARINIC AGONISTS TO TREAT IMPULSE CONTROL DISORDERS 审中-公开
    治疗肿瘤控制障碍的药物治疗

    公开(公告)号:US20070259859A1

    公开(公告)日:2007-11-08

    申请号:US11741976

    申请日:2007-04-30

    IPC分类号: A61K31/5513

    CPC分类号: A61K31/5513

    摘要: The invention relates to a novel use of compounds and pharmaceutically acceptable salts thereof, which are muscarinic, for example muscarine-1 (M1) agonists. These compounds are useful for the preparation of medicaments for treatment, amelioration or prevention of impulse control disorders. These include impulse control disorders ‘Not Elsewhere Classified,’ such as intermittent explosive disorder, pyromania, kleptomania, pathological gambling and trichotillomania, and impulse control disorders ‘Not Otherwise Specified,’ such as compulsive buying disorder, binge eating and binge drinking disorder, impulsive self-injurious behavior, sexual addictions, compulsive Internet use, and excessive mobile phone use.

    摘要翻译: 本发明涉及毒蕈碱的化合物及其药学上可接受的盐的新用途,例如毒蕈碱-1(M 1 H 1)激动剂。 这些化合物可用于制备用于治疗,改善或预防冲动控制障碍的药物。 这些包括脉冲控制障碍“非其他分类”,如间歇性爆发性疾病,原发性幽门螺杆菌,轻度恐怖症,病理性赌博和拔毛病,以及冲动控制障碍“无其他指定”,如强迫性购买障碍,暴饮暴食和暴饮暴食,冲动 自我伤害行为,性成瘾,互联网强制使用和手机使用过多。

    USE OF 5-HT6 ANTAGONISTS TO PREVENT RELAPSE INTO ADDICTION
    4.
    发明申请
    USE OF 5-HT6 ANTAGONISTS TO PREVENT RELAPSE INTO ADDICTION 审中-公开
    5-HT6拮抗剂的使用,以防止患者继续使用

    公开(公告)号:US20080171779A1

    公开(公告)日:2008-07-17

    申请号:US12013898

    申请日:2008-01-14

    IPC分类号: A61K31/415 A61P25/30

    CPC分类号: A61K31/415

    摘要: A novel use of compounds and pharmaceutically acceptable salts thereof, which are 5-HT6 antagonists, are disclosed. In one embodiment, the invention relates to the use of these compounds or pharmaceutical compositions comprising these compounds for preventing relapse into addiction, for example, relapse into addiction to substances of abuse, including opiates, hallucinogens, inhalants, phencyclidine, amphetamines, cocaine, cannabis, nicotine, and alcohol, relapse into addiction to certain medicines, including sedatives, hypnotics and anxiolytics, and relapse into certain addictive behaviors, including gambling.

    摘要翻译: 公开了其作为5-HT 6拮抗剂的化合物及其药学上可接受的盐的新用途。 在一个实施方案中,本发明涉及这些化合物或包含这些化合物的药物组合物用于预防复发成瘾的用途,例如复发成瘾物质,包括阿片剂,致幻剂,吸入剂,苯环利定,苯丙胺,可卡因,大麻 ,尼古丁和酒精,对某些药物,包括镇静剂,催眠药和抗焦虑药物复发,并复发到某些令人上瘾的行为,包括赌博。